Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Adding Pfizer’s cancer drug Braftovi to standard treatments helped people with a form of colorectal cancer live longer without their disease worsening than those who got the typical care alone ...

which suppresses the immune system from fighting cancer cells. And although Pfizer's deal is with a China-based company, Pfizer said it plans to manufacture drug substance for SSGJ-7807 in Sanford ...